Patents by Inventor Richard Leonard Elliott
Richard Leonard Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016941Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.Type: ApplicationFiled: March 23, 2021Publication date: January 18, 2024Applicant: Antabio SASInventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Publication number: 20220112169Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.Type: ApplicationFiled: July 25, 2019Publication date: April 14, 2022Applicant: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Publication number: 20210347748Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.Type: ApplicationFiled: July 25, 2019Publication date: November 11, 2021Applicant: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Patent number: 11000511Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.Type: GrantFiled: March 21, 2018Date of Patent: May 11, 2021Assignee: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Jonathan Mark Sutton, Michael Steven Bodnarchuk, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, David Edward Clark, Richard Leonard Elliott, Lilha Beyria
-
Publication number: 20200155509Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.Type: ApplicationFiled: March 21, 2018Publication date: May 21, 2020Applicant: Antabio SASInventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
-
Patent number: 9890152Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: GrantFiled: June 19, 2015Date of Patent: February 13, 2018Assignee: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
-
Publication number: 20160016948Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: ApplicationFiled: June 19, 2015Publication date: January 21, 2016Applicant: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
-
Patent number: 8546376Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: GrantFiled: September 17, 2010Date of Patent: October 1, 2013Assignee: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20120238541Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: ApplicationFiled: September 17, 2010Publication date: September 20, 2012Applicant: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20100311740Abstract: This invention relates to newly identified imidazopyridine compounds of formula (I), to the use of such compounds in treating GERD and the like.Type: ApplicationFiled: June 28, 2006Publication date: December 9, 2010Inventors: Mark James Bamford, Richard Leonard Elliott, Gerard Martin Paul Giblin, Antoinette Naylor, Terence Aaron Chal, Andrew Kenneth Takle, Jason Witherington
-
Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases
Publication number: 20080255358Abstract: Disclosed are imidazopyridine compounds having the formula:Type: ApplicationFiled: March 22, 2006Publication date: October 16, 2008Inventors: Mark James Bamford, Emmanuel Hubert Demont, Richard Leonard Elliott, Gerard Martin Paul Giblin, Antoinette Naylor, Terence Aaron Panchal, Jason Witherington -
Patent number: 7410984Abstract: The present invention relates to novel pyridone derivatives capable of inhibiting ?4 integrin mediated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by the inhibition of cell adhesion.Type: GrantFiled: August 8, 2003Date of Patent: August 12, 2008Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Jason Witherington, Richard Leonard Elliott
-
Patent number: 7169924Abstract: Compound of formula (I): are disclosed in which: R1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-6)alkyl, C(1-6)alkoxy, C(1-6)alkylthio, hydroxy, halogen, CN, and mono to perfluoro-C(1-4)alkyl; R2 is halogen, C(1-3)alkyl, C(1-3)alkoxy, hydroxyC(1-3)alkyl, C(1-3)alkylthio, C(1-3)alkylsulphinyl, aminoC(1-3)alkyl, mono- or di-C(1-3)alkylaminoC(1-3)alkyl, C(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkoxyC(1-3)alkylcarbonylaminoC(1-3)alkyl, C(1-3)alkylsulphonylaminoC(1-3)alkyl, C(1-3)alkylcarboxy, C(1-3)alkylcarboxyC(1-3)alkyl, and R3 is hydrogen, halogen, C(1-3)alkyl, or hydroxyC(1-3)alkcyl; or R2 and R3 together with the pyrimidone ring carbon atoms to which they are attached form a fused 5-or 6-membered carbocyclic ring; or R2 and R3 together with the pyrimidone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or difType: GrantFiled: October 5, 2001Date of Patent: January 30, 2007Assignee: SmithKline Beecham plcInventors: Richard Leonard Elliott, Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith
-
Patent number: 6762034Abstract: Resorufin derivative as a substance for cytochrome P450 enzyme.Type: GrantFiled: January 2, 2002Date of Patent: July 13, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Jacqueline Carol Bloomer, Richard Leonard Elliott, Colin Andrew Leach
-
Patent number: 6756209Abstract: Coumarin derivatives as substrates for cytochrome P450 enzyme.Type: GrantFiled: June 11, 2001Date of Patent: June 29, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Ramesh B. Bambal, Richard Leonard Elliott
-
Publication number: 20040058941Abstract: Compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating athereosclerosis.Type: ApplicationFiled: September 2, 2003Publication date: March 25, 2004Inventors: Richard Leonard Elliott, Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith
-
Patent number: 5665717Abstract: Carbacephalosporin compounds of formula (I), ##STR1## salts thereof, processes for their synthesis and uses thereof, wherein: R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a carboxy protecting group or a pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 represent hydrogen or a substituent; R.sup.4 and R.sup.7 may be replaced by a chemical bond between the two carbon atoms shown; R.sup.5 and R.sup.6 may be linked together into a cyclic system. The compounds (I) have antibacterial properties.Type: GrantFiled: January 18, 1996Date of Patent: September 9, 1997Assignee: Pfizer Inc.Inventors: Richard Leonard Elliott, Neville Hubert Nicholson, Andrew Kenneth Takle